Prana Biotechnology Current Ratio 2006-2020 | ATHE

Prana Biotechnology current ratio from 2006 to 2020. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Prana Biotechnology Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2020-12-31 $0.03B $0.00B 12.28
2020-06-30 $0.01B $0.00B 3.62
2019-12-31 $0.01B $0.00B 4.43
2019-06-30 $0.01B $0.00B 5.98
2018-12-31 $0.01B $0.00B 4.37
2018-06-30 $0.01B $0.00B 7.09
2017-12-31 $0.02B $0.00B 12.12
2017-06-30 $0.02B $0.00B 15.99
2016-12-31 $0.02B $0.00B 10.66
2016-06-30 $0.03B $0.00B 14.34
2015-12-31 $0.03B $0.00B 16.41
2015-06-30 $0.04B $0.00B 15.39
2014-12-31 $0.03B $0.00B 12.09
2014-06-30 $0.04B $0.00B 10.54
2013-12-31 $0.02B $0.00B 5.16
2013-06-30 $0.02B $0.00B 5.48
2012-12-31 $0.01B $0.00B 3.81
2012-06-30 $0.01B $0.00B 4.23
2011-12-31 $0.01B $0.00B 3.64
2011-06-30 $0.01B $0.00B 4.31
2010-12-31 $0.00B $0.00B 3.25
2010-06-30 $0.01B $0.00B 4.48
2009-12-31 $0.01B $0.00B 9.53
2009-06-30 $0.00B $0.00B 5.68
2008-12-31 $0.01B $0.00B 4.04
2008-06-30 $0.01B $0.00B 6.65
2007-12-31 $0.01B $0.00B 4.94
2007-06-30 $0.01B $0.00B 4.43
2006-12-31 $0.01B $0.00B 10.29
2006-06-30 $0.01B $0.00B 6.43
2005-12-31 $0.01B $0.00B 14.41
2005-06-30 $0.02B $0.00B 8.38
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.029B $0.003B
Prana Biotechnology was established to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. Their mission is to develop diagnostic and therapeutic drugs to treat the central disease pathways that cause degeneration of the brain as the aging process progresses. Prana's technology has emerged from its researchers at prominent international institutions such as Massachusetts General Hospital at Harvard Medical School and the University of Melbourne.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71